Compare WLKP & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLKP | SDGR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.4M | 856.7M |
| IPO Year | 2014 | 2020 |
| Metric | WLKP | SDGR |
|---|---|---|
| Price | $21.76 | $12.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 54.1K | ★ 1.6M |
| Earning Date | 05-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 8.63% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,135,896,000.00 | $255,869,000.00 |
| Revenue This Year | $3.88 | $23.92 |
| Revenue Next Year | $12.71 | $19.52 |
| P/E Ratio | $15.30 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $17.75 | $11.11 |
| 52 Week High | $24.58 | $27.63 |
| Indicator | WLKP | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 38.84 |
| Support Level | $21.83 | N/A |
| Resistance Level | $22.40 | $19.51 |
| Average True Range (ATR) | 0.50 | 0.71 |
| MACD | 0.02 | 0.19 |
| Stochastic Oscillator | 81.94 | 30.74 |
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.